Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beyond Air, Inc.XAIR · Entity 8379 | Director | November 04, 2025 | November 07, 2025 |
| Bone Biologics CorpBBLG · Entity 8560 | Director | September 18, 2023 | September 20, 2023 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Financial Officer | August 13, 2026 | August 17, 2026 |
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director | December 16, 2025 | December 18, 2025 |
| Valeritas Holdings Inc.VLRX · Entity 152233 | See Remarks | March 07, 2019 | March 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beyond Air, Inc.
Report date November 04, 2025 · Filed November 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-04 · Disposition to issuer · Disposed 2,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 2,250 |
Reported balance
After 2025-11-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-04 · Grant · Acquired 2,250 · Balance 2,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-04 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 2,000 |
Reported balance
After 2025-11-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-04 · Grant · Acquired 2,000 · Balance 2,000 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-11-04 · Disposition to issuer · Disposed 1,500 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,500 |
Reported balance
After 2025-11-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-11-04 · Grant · Acquired 1,500 · Balance 1,500 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-11-04 · Disposition to issuer · Disposed 1,000 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,000 |
Reported balance
After 2025-11-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-11-04 · Grant · Acquired 1,000 · Balance 1,000 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.89 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-11-04 · Disposition to issuer · Disposed 3,750 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 3,750 |
Reported balance
After 2025-11-04 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-11-04 · Grant · Acquired 3,750 · Balance 3,750 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.
F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Bone Biologics Corp
Report date September 18, 2023 · Filed September 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2033-09-13 | Direct | 85,763 |
Reported balance
After 2023-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-18 · Grant · Acquired 85,763 · Balance 85,763 F1: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.41 · Expires 2027-08-23 | Direct | 1,229 |
Reported balance
Holding disclosure · report date 2023-09-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,229 F2: This option is fully vested as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $105.60 · Expires 2032-01-01 | Direct | 291 |
Reported balance
Holding disclosure · report date 2023-09-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 291 F2: This option is fully vested as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $157.50 · Expires 2031-10-26 | Direct | 99 |
Reported balance
Holding disclosure · report date 2023-09-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 99 F2: This option is fully vested as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $157.50 · Expires 2031-10-15 | Direct | 677 |
Reported balance
Holding disclosure · report date 2023-09-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 677 F2: This option is fully vested as of the date of this report. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.
F2: This option is fully vested as of the date of this report.
Dyne Therapeutics, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,766 |
Reported balance
After 2026-08-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-13 · Sale · Disposed 1,797 · Balance 119,766 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 106,451 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F3: Includes 106,451 unvested RSUs.
SAB Biotherapeutics, Inc.
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2035-12-16 | Direct | 150,000 |
Reported balance
After 2025-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-16 · Grant · Acquired 150,000 · Balance 150,000 F1: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.
F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
Valeritas Holdings Inc.
Report date March 07, 2019 · Filed March 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2029-03-07 | Direct | 280,000 |
Reported balance
After 2019-03-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-07 · Grant · Acquired 280,000 · Balance 280,000 F1: 25% of the option shall vest on March 07, 2020, the one-year anniversary of the date of grant. The remaining shares underlying the option vest in substantially equal quarterly installments for 8 quarters after such one-year anniversary, such that the option will fully vest on March 07, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option shall vest on March 07, 2020, the one-year anniversary of the date of grant. The remaining shares underlying the option vest in substantially equal quarterly installments for 8 quarters after such one-year anniversary, such that the option will fully vest on March 07, 2022.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEO PHARMACEUTICALS, INC.
Report date January 19, 2023 · Filed January 19, 2023
Section 16 reporting ended · disclosed 2023-01-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2030-01-05 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-19 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 · Expires 2031-02-05 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-19 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.67 · Expires 2032-02-15 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-19 · Disposition to issuer · Disposed 218,800 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Editas Medicine, Inc.
Report date March 08, 2025 · Filed March 27, 2025
Section 16 reporting ended · disclosed 2025-03-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2035-03-07 | Direct | 275,100 |
Reported balance
After 2025-03-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-08 · Grant · Acquired 275,100 · Balance 275,100 F1: This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2035-03-07 | Direct | 70,000 |
Reported balance
After 2025-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-08 · Grant · Acquired 70,000 · Balance 70,000 F2: This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029.
F2: This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2023 Filed Sep 20, 2023 18:54 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 85,763 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001493152-23-033177 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,763 Underlying: Common Stock · 85,763 shares Expires 2033-09-13 F1 · derivative.exercise_date: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant. Read SEC document |
| May 17, 2023 Filed May 18, 2023 21:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 155,800 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001415889-23-008293 · form4-05182023_090554.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,800 Underlying: Common Stock · 155,800 shares Expires 2033-05-16 F2 · derivative.exercise_date: This option was granted on May 17, 2023 and is scheduled to vest over four years, with 25% of the shares to vest on May 17, 2024 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through May 17, 2027. Read SEC document |
| May 17, 2023 Filed May 18, 2023 21:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 77,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-008293 · form4-05182023_090554.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,900 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on May 17, 2024 continuing through May 17, 2027. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:01 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001437749-23-009554 · rdgdoc.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-04-03 F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option vest over a three-year period, vesting 1/36 monthly beginning with the month following the Reporting Person's commencement of service as a director (April 3, 2023). This represents the initial grant to the Reporting Person as a member of the Board of Directors. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001493152-23-010273 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-03-28 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2023, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:10 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 2,000 | $6.82 | $13,634.00 |
DisclosureSEC source: 0001493152-23-008245 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,342 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.815 to $6.817, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 218,800 | Not disclosed Strike: $3.67 | Not disclosed |
DisclosureSEC source: 0000899243-23-002182 · doc4.xml · derivative · entry 3 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 218,800 shares Expires 2032-02-15 F1 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F1 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $9.12 | Not disclosed |
DisclosureSEC source: 0000899243-23-002182 · doc4.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-02-05 F1 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F1 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:11 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $6.70 | Not disclosed |
DisclosureSEC source: 0000899243-23-002182 · doc4.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2030-01-05 F1 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F1 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| August 23, 2022 Filed Mar 8, 2023 11:20 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 36,845 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001493152-23-006966 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,516 Underlying: Common Stock · 36,845 shares Expires 2027-08-23 F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 13:33 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.87 | $0.00 |
DisclosureSEC source: 0001493152-22-006149 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2022, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 17:00 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 218,800 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001628280-22-003056 · wf-form4_164513518447933.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,800 Underlying: Common Stock · 218,800 shares Expires 2032-02-15 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 01, 2022 Filed Feb 28, 2022 11:02 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 8,722 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001493152-22-005543 · ownership.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,671 Underlying: Common Stock · 8,722 shares Expires 2032-01-01 F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant. Read SEC document |
| October 26, 2021 Filed Feb 28, 2022 11:02 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 2,949 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0001493152-22-005543 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,949 Underlying: Common Stock · 2,949 shares Expires 2031-10-26 Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:57 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001493152-21-005623 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-03-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2021, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| February 16, 2021 Filed Mar 3, 2021 22:50 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Exercise / conversionTranche B Warrant (Right to Buy) · Derivative | 1,171 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001493152-21-005312 · ownership.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,171 shares Expires 2021-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Mar 3, 2021 22:50 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Exercise / conversionCommon Stock | 1,171 | $4.25 | $4,976.75 |
DisclosureSEC source: 0001493152-21-005312 · ownership.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Apr 16, 2021 16:05 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.12 | $0.00 |
DisclosureSEC source: 0000899243-21-016104 · doc4.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-05 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 5, 2021 through February 5, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 16:31 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-20-000827 · doc4.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-01-05 F1 · derivative.exercise_date: 25% of this option shall vest on January 6, 2021, and the remainder of this option shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Company. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 16:56 UTC | Valeritas Holdings Inc. VLRX · Entity 152233 | GrantEmployee Stock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001697616-19-000002 · wf-form4_155208217474070.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: 25% of the option shall vest on March 07, 2020, the one-year anniversary of the date of grant. The remaining shares underlying the option vest in substantially equal quarterly installments for 8 quarters after such one-year anniversary, such that the option will fully vest on March 07, 2022. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 16:51 UTC | Valeritas Holdings Inc. VLRX · Entity 152233 | GrantEmployee Stock Option (Right to Buy) · Derivative | 363,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001697616-18-000005 · wf-form4_154275069279424.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,000 Underlying: Common Stock · 363,000 shares Expires 2028-11-19 F1 · derivative.exercise_date: 50% of the option shall vest on November 19, 2019, the one-year anniversary of the date of grant. The remaining shares underlying the option vest in substantially equal quarterly installments for 4 quarters after such one-year anniversary, such that the option will fully vest on November 19, 2020. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 21:24 UTC | Beyond Air, Inc. AITB · Entity 8379 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001493152-18-012104 · ownership.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2028-08-12 F1 · derivative.exercise_date: The Options will vest as to 25% of the shares on December 31, 2018 and on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| February 16, 2018 Filed Apr 30, 2018 21:37 UTC | Beyond Air, Inc. AITB · Entity 8379 | Exercise / conversionTranche A Warrant (right to buy) · Derivative | 1,171 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001178913-18-001369 · zk1821548.xml · derivative · entry 4 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,171 shares Expires 2018-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Apr 30, 2018 21:37 UTC | Beyond Air, Inc. AITB · Entity 8379 | PurchaseTranche B Warrant (right to buy) · Derivative | 1,171 | $0.01 Strike: $4.25 | $11.71 |
DisclosureSEC source: 0001178913-18-001369 · zk1821548.xml · derivative · entry 3 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171 Underlying: Common stock · 1,171 shares Expires 2021-02-15 Read SEC document |
| February 16, 2018 Filed Apr 30, 2018 21:37 UTC | Beyond Air, Inc. AITB · Entity 8379 | PurchaseTranche A Warrant (right to buy) · Derivative | 1,171 | $0.01 Strike: $4.25 | $11.71 |
DisclosureSEC source: 0001178913-18-001369 · zk1821548.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171 Underlying: Common stock · 1,171 shares Expires 2018-02-19 Read SEC document |
| February 16, 2018 Filed Apr 30, 2018 21:37 UTC | Beyond Air, Inc. AITB · Entity 8379 | Exercise / conversionCommon Stock | 1,171 | $4.25 | $4,976.75 |
DisclosureSEC source: 0001178913-18-001369 · zk1821548.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 16:41 UTC | Valeritas Holdings Inc. VLRX · Entity 152233 | GrantEmployee Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001697616-18-000002 · wf-form4_151873089239649.xml · derivative · entry 1 Lucera Erick · CIK 0001697616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2028-02-13 F1 · derivative.exercise_date: 25% of the option shall vest on February 13, 2019, the one-year anniversary of the date of grant. The remaining shares underlying the option vest in substantially equal quarterly installments for 8 quarters after such one-year anniversary. Read SEC document |
| May 22, 2017 Filed May 23, 2017 16:17 UTC | Valeritas Holdings Inc. VLRX · Entity 152233 | PurchaseCommon Stock | 500 | $4.95 | $2,475.00 |
DisclosureSEC source: 0001697616-17-000002 · wf-form4_149557060702939.xml · nonDerivative · entry 2 Lucera Erick · CIK 0001697616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
| May 22, 2017 Filed May 23, 2017 16:17 UTC | Valeritas Holdings Inc. VLRX · Entity 152233 | PurchaseCommon Stock | 1,000 | $4.95 | $4,950.00 |
DisclosureSEC source: 0001697616-17-000002 · wf-form4_149557060702939.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:43 UTC | Valeritas Holdings Inc. VLRX · Entity 152233 | GrantEmployee Stock Option (Right to Buy) · Derivative | 73,800 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0000899243-17-008671 · doc4.xml · derivative · entry 2 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,800 Underlying: Common Stock · 73,800 shares Expires 2027-03-23 F1 · derivative.exercise_date: 25% of the option shall vest on March 23, 2018, the one year anniversary of the date of grant. The remaining shares underlying the option vest in substantially equal quarterly installments for 12 quarters after such six-month anniversary. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:43 UTC | Valeritas Holdings Inc. VLRX · Entity 152233 | PurchaseCommon Stock | 3,000 | $10.00 | $30,000.00 |
DisclosureSEC source: 0000899243-17-008671 · doc4.xml · nonDerivative · entry 1 Lucera Erick · CIK 0001697616 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.